About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

8.150 +0.320 (+4.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces Reverse Stock Split
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Appoints Michael Grissinger to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
From Adicet Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.